Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older mRESVIA is the only RSV vaccine available in a pre-filled syringe. This format offers a convenient, ready-to-use formulation that simplifies the process of administering the vaccine, saving healthcare professionals time and reducing the risk of administrative errors. Supply of mRESVIA is anticipated in Canada in early 2025.